Overall, the three different antibiotics necessitated the development of three separate protocols for selective oxidation.

Almost all living things have an internal 24-hour clock that remains accurate regardless of temperature or other ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

In the depths of Scarisoara cave in Romania sits one of the world’s biggest underground glaciers, a monumental slab of ice the size of roughly 40 Olympic swimming pools that began to form around ...

A University of Alberta research team has identified a new drug target to treat harmful E. coli bacteria—which cause nearly 250,000 deaths a year from urinary tract infections (UTI) and are becoming ...

Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Whether it’s the ocean’s deepest hydrothermal vents or tall ...

Gynecologists long viewed bacterial vaginosis as solely a women’s issue — until a study that treated their male partners, too, proved otherwise. By Rachel E. Gross Rarely does a single study change ...

People with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) wake up every morning to relentless abdominal pain — the kind that makes ordinary activities feel impossible. The pain ...

A Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two harmonized bacteria to destroy tumors even in patients with weakened immune ...

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group. The ASPEN trial demonstrated that ...